关键词：高胆固醇血症；低密度脂蛋白胆固醇；心血管病
摘 要：Hypercholesterolemia is a condition characterized by very high levels of total cholesterol and LDL cholesterol in the blood. High cholesterol levels, in turn, can lead to CVDs such as atherosclerosis and stroke. The normal physiological range of total blood cholesterol is 140-200 mg/dL. However, blood cholesterol consists of various individual components such as LDL cholesterol and HDL cholesterol. While LDL delivers cholesterol to the body, HDL removes cholesterol from the cells by reverse cholesterol transport to the liver. Owing to their distinct roles, these components are individually evaluated to determine the dyslipidemic status of an individual. FH is the inheritable form of hypercholesterolemia characterized by elevated levels of total cholesterol and LDL cholesterol. HeFH is the condition inherited because of the presence of one abnormal copy of the LDLR gene. HoFH is characterized by the presence of abnormal copies of both the LDLR alleles.
目 录：

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

03.1 Market Overview

03.2 Product Offerings

04. Market Research Methodology

04.1 Market Research Process

04.2 Research Methodology

05. Introduction

06. Market Landscape

06.1 Market Overview

06.2 Market Size and Forecast

06.3 Five Forces Analysis

07. Clinical Pipeline Portfolio

08. Market Segmentation by Type of Disease

09. Market Segmentation by MoA

09.1 Global Statins Market

09.1.1 Market Size and Forecast

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Vendor Landscape

18.1 Competitive Scenario

18.1.1 Key News

18.1.2 Mergers and Acquisitions

18.2 Market Share Analysis 2013

18.3 Other Prominent Vendors

18.4 Future Players Expected to Tap the Market

19. Key Vendor Analysis

19.1 AbbVie Inc.

19.1.1 Key Facts

19.1.2 Business Overview

19.1.3 Product Segmentation by Revenue 2013

19.1.4 Product Segmentation by Revenue 2012 and 2013

19.1.5 Sales by Geography

19.1.6 Business Strategy

19.1.7 Key Developments

19.1.8 SWOT Analysis

19.1.9 Strengths

19.1.10 Weaknesses

19.1.11 Opportunities

19.1.12 Threats

19.2 AstraZeneca plc

19.2.1 Key Facts

19.2.2 Business Overview

19.2.3 Business Segmentation by Revenue 2013

19.2.4 Business Segmentation by Revenue 2011-2013

19.2.5 Sales by Geography

19.2.6 Business Strategy

19.2.7 Key Developments

19.2.8 SWOT Analysis

19.2.9 Strengths

19.2.10 Weaknesses

19.2.11 Opportunities

19.2.12 Threats

19.3 Merck & Co. Inc.

19.3.1 Key Facts

19.3.2 Business Overview

19.3.3 Business Segmentation by Revenue 2013

19.3.4 Business Segmentation by Revenue 2012 and 2013

19.3.5 Sales by Geography

19.3.6 Business Strategy

19.3.7 Key Developments

19.3.8 SWOT Analysis

19.3.9 Strengths

19.3.10 Weaknesses

19.3.11 Opportunities

19.3.12 Threats

19.4 Pfizer Inc.

19.4.1 Key Facts

19.4.2 Business Overview

19.4.3 Business Segmentation by Revenue 2013

19.4.4 Business Segmentation by Revenue 2012 and 2013

19.4.5 Sales by Geography

19.4.6 Business Strategy

19.4.7 Key Developments

19.4.8 SWOT Analysis

19.4.9 Strengths

19.4.10 Weaknesses

19.4.11 Opportunities

19.4.12 Threats

20. Other Reports in this Series